Trump Administration’s N.I.H. and F.D.A. Cuts Could Curtail New Drug Development, Budget Office Says

The Congressional Budget Office (CBO) has warned that the Trump administration's proposed cuts to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) could hinder the development of new drugs. The CBO report suggests that the administration's budget plan, which includes a 22% reduction in NIH funding and a 31% decrease in FDA funding, would lead to a decline in the number of new drugs approved each year. This could potentially impact the availability of innovative treatments for patients and the competitiveness of the American pharmaceutical industry. The report highlights the importance of sustained investment in medical research and regulatory oversight to support the development of new drugs and ensure their safety and efficacy. The proposed budget cuts have raised concerns among healthcare professionals, patient advocates, and industry stakeholders about the potential consequences for public health and the future of pharmaceutical innovation in the United States.